GSK's Dovato meets primary goal in late-stage HIV study

British Drugmaker GlaxoSmithKline Plc on Wednesday said its two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients for 48 weeks at similar levels as the patients' previous three-drug treatment.